Patients with advanced renal cell carcinoma treated with first-line sunitinib - Hypothyroidism a potential indicator of prognosis

Trial Profile

Patients with advanced renal cell carcinoma treated with first-line sunitinib - Hypothyroidism a potential indicator of prognosis

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top